Emerging role of combination of all-trans retinoic acid and interferon-gamma as chemoimmunotherapy in the management of human glioblastoma

Neurochemical Research

Volumn 32, Issue 12, 2007, Pages 2203-2209

  Haque, Azizul ^a,b   Banik, Naren L ^a,b   Ray, Swapan K ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Apoptosis; ATRA; Chemoimmunotherapy; Cross presentation; Gamma interferon inducible lysosomal thiolreductase; Glioblastoma; IFN ; Invariant chain

Indexed keywords

B7 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; CYCLOOXYGENASE 2; EPHRIN RECEPTOR A2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; GLYCOPROTEIN GP 100; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELANOMA ANTIGEN 1; PROTEIN AIM 2; PROTEIN GLEA1; PROTEIN GLEA2; PROTEIN PHF 3; PROTEIN YKL 40; RETINOIC ACID; STEM CELL FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; DRUG EFFICACY; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; MALIGNANT NEOPLASTIC DISEASE; NERVE CELL DIFFERENTIATION; NERVE CELL NECROSIS; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CANCER VACCINES; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA, RECOMBINANT; TRETINOIN;

EID: 35848955916     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11064-007-9420-z     Document Type: Review

References (50)

1. Boudreau CR, Yang I, Liau LM (2005) Gliomas: advances in molecular analysis and characterization. Surg Neurol 64:286-294
2. Palanichamy K, Erkkinen M, Chakravarti A (2006) Predictive and prognostic markers in human glioblastomas. Curr Treat Options Oncol 7:490-504
3. Wong ML, Kaye AH, Hovens CM (2007) Targeting malignant glioma survival signalling to improve clinical outcomes. J Clin Neurosci 14:301-308
4. Hsieh JC, Lesniak MS (2005) Surgical management of high-grade gliomas. Expert Rev Neurother 5:S33-S39
5. Paganelli G, Bartolomei M, Grana C, Ferrari M, Rocca P, Chinol M (2006) Radioimmunotherapy of brain tumor. Neurol Res 28:518-522
6. Nieder C, Grosu AL, Astner S, Molls M (2005) Treatment of unresectable glioblastoma multiforme. Anticancer Res 25:4605-4610
7. Nieder C, Adam M, Molls M, Grosu AL (2006) Therapeutic options for recurrent high-grade glioma in adult patients: recent advances. Crit Rev Oncol Hematol 60:181-193
8. Robins HI, Chang S, Butowski N, Mehta M (2007) Therapeutic advances for glioblastoma multiforme: current status and future prospects. Curr Oncol Rep 9:66-70
9. Ng SS, Gao Y, Chau DH, Li GH, Lai LH, Huang PT, Huang CF, Huang JJ, Chen YC, Kung HF, Lin MC (2007) A novel glioblastoma cancer gene therapy using AAV-mediated long-term expression of human TERT C-terminal polypeptide. Cancer Gene Ther 14:561-572
10. Fan X, Salford LG, Widegren B (2007) Glioma stem cells: evidence and limitation. Semin Cancer Biol 17:214-218
11. Nikanjam M, Blakely EA, Bjornstad KA, Shu X, Budinger TF, Forte TM (2007) Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme. Int J Pharm 328:86-94
12. Tang J, Flomenberg P, Harshyne L, Kenyon L, Andrews DW (2005) Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells. Clin Cancer Res 11:5292-9529
13. Carpentier AF, Meng Y (2006) Recent advances in immunotherapy for human glioma. Curr Opin Oncol 18:631-636
14. Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC (2004) Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res 64:9160-9166
15. Yamanaka R, Abe T, Yajima N, Tsuchiya N, Homma J, Kobayashi T, Narita M, Takahashi M, Tanaka R (2003) Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer 89:1172-1179
16. Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ (2004) Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64:4973-4979
17. van der Bruggen P, Van den Eynde BJ (2006) Processing and presentation of tumor antigens and vaccination strategies. Curr Opin Immunol 18:98-104
18. Thompson JA, Dissanayake SK, Ksander BR, Knutson KL, Disis ML, Ostrand-Rosenberg S (2006) Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain. Cancer Res 66:1147-1154
19. Schiltz PM, Gomez GG, Read SB, Kulprathipanja NV, Kruse CA (2002) Effects of IFN-γ and interleukin-1β on major histocompatibility complex antigen and intercellular adhesion molecule-1 expression by 9L gliosarcoma: relevance to its cytolysis by alloreactive cytotoxic T lymphocytes. J Interferon Cytokine Res 22:1209-1216
20. Gomez GG, Kruse CA (2006) Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gene Ther Mol Biol 10:133-146
21. Gattoni A, Parlato A, Vangieri B, Bresciani M, Derna R (2006) Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts). Clin Ter 157:377-386
22. Haque A, Das A, Hajiaghamohseni LM, Younger A, Banik NL, Ray SK (2006) Induction of apoptosis and immune response by all-trans retinoic acid plus interferon-gamma in human glioblastoma T98G and U87MG cells. Cancer Immunol Immunother 56:615-625
23. Tao Y, Yang Y, Wang W (2006) Effect of all-trans-retinoic acid on the differentiation, maturation and functions of dendritic cells derived from cord blood monocytes. FEMS Immunol Med Microbiol 47:444-450
24. Mathew JS, Sharma RP (2000) Effect of all-trans-retinoic acid on cytokine production in a murine macrophage cell line. Int J Immunopharmacol 22:693-706
25. Wang KC, Cheng AL, Chuang SE, Hsu HC, Su IJ (2000) Retinoic acid-induced apoptotic pathway in T-cell lymphoma: Identification of four groups of genes with differential biological functions. Exp Hematol 28:1441-1450
26. Pohl J, LaFace D, Sands JF (1993) Transcription of retinoic acid receptor genes in transgenic mice increases CD8 T-cell subset. Mol Biol Rep 17:135-142
27. Westervelt P, Pollock JL, Oldfather KM, Walter MJ, Ma MK, Williams A, DiPersio JF, Ley TJ (2002) Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia. Proc Natl Acad Sci USA 99:9468-9473
28. Luo XM, Ross AC (2005) Physiological and receptor-selective retinoids modulate interferon gamma signaling by increasing the expression, nuclear localization, and functional activity of interferon regulatory factor-1. J Biol Chem 280:36228-36236
29. Aoudjit F, Bosse M, Stratowa C, Voraberger G, Audette M (1994) Regulation of intercellular adhesion molecule-1 expression by retinoic acid: analysis of the 5' regulatory region of the gene. Int J Cancer 58:543-549
30. Matloubian M, Concepcion RJ, Ahmed R (1994) CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol 68:8056-8063
31. Mautner J, Jaffee EM, Pardoll DM (2005) Tumor-specific CD4+ T cells from a patient with renal cell carcinoma recognize diverse shared antigens. Int J Cancer 115:752-759
32. Kusmartsev S, Cheng F, Yu B, Nefedova Y, Sotomayor E, Lush R, Gabrilovich D (2003) All-trans retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res 63:4441-4449
33. Mirza N, Fishman M, Fricke I, Dunn M, Neuger AM, Frost TJ, Lush RM, Antonia S, Gabrilovich DI (2006) All-trans retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 66:9299-9307
34. Mocellin S, Wang E, Marincola FM (2001) Cytokines and immune response in the tumor microenvironment. J Immunother 24:392-407
35. Sinha P, Clements VK, Miller S, Ostrand-Rosenberg S (2005) Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression. Cancer Immunol Immunother 54:1137-1142
36. Haque MA, Li P, Jackson SK, Zarour HM, Hawes JW, Phan UT, Maric M, Cresswell P, Blum JS (2002) Absence of gamma-interferon-inducible lysosomal thiol reductase in melanomas disrupts T cell recognition of select immunodominant epitopes. J Exp Med 195:1267-1277
37. Facoetti A, Nano R, Zelini P, Morbini P, Benericetti E, Ceroni M, Campoli M, Ferrone S (2005) Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Clin Cancer Res 11:8304-8311
38. O'Donnell PW, Haque A, Klemsz MJ, Kaplan MH, Blum JS (2004) Induction of the antigen processing enzyme IFN-gamma-inducible lysosomal thiol reductase in melanoma cells is STAT1-dependent but CIITA-independent. J Immunol 173:731-735
39. Maccalli C, Li YF, El-Gamil M, Rosenberg SA, Robbins PF (2003) Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4+ T lymphocytes. Cancer Res 63:6735-6743
40. Zehbe I, Hohn H, Pilch H, Neukirch C, Freitag K, Maeurer MJ (2005) Differential MHC class II component expression in HPV-positive cervical cancer cells: implication for immune surveillance. Int J Cancer 117:807-815
41. Rangel LB, Agarwal R, Sherman-Baust CA, Mello-Coelho V, Pizer ES, Ji H, Taub DD, Morin PJ (2004) Anomalous expression of the HLA-DR α and β chains in ovarian and other cancers. Cancer Biol Ther 3:1021-1027
42. Haque A, Blum JS (2005) New insights in antigen processing and epitope selection: development of novel immunotherapeutic strategies for cancer, autoimmunity and infectious diseases. J Biol Regul Homeost Agents 19:93-104
43. Hatano M, Eguchi J, Tatsumi T, Kuwashima N, Dusak JE, Kinch MS, Pollack IF, Hamilton RL, Storkus WJ, Okada H (2005) EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia 7:717-722
44. Nutt CL, Betensky RA, Brower MA, Batchelor TT, Louis DN, Stemmer-Rachamimov AO (2005) YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas. Clin Cancer Res 11:2258-2264
45. Akasaki Y, Liu G, Chung NH, Ehtesham M, Black KL, Yu JS (2004) Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma. J Immunol 173:4352-4359
46. Cetin N, Dienel G, Gokden M (2005) CD117 expression in glial tumors. J Neurooncol 75:195-202
47. Pallasch CP, Struss AK, Munnia A, Konig J, Steudel WI, Fischer U, Meese E (2005) Autoantibodies against GLEA2 and PHF3 in glioblastoma: tumor-associated autoantibodies correlated with prolonged survival. Int J Cancer 117:456-459
48. Liu G, Ying H, Zeng G, Wheeler CJ, Black KL, Yu JS (2004) HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res 64:4980-4986
49. Dissanayake SK, Thompson JA, Bosch JJ, Clements VK, Chen PW, Ksander BR, Ostrand-Rosenberg S (2004) Activation of tumor-specific CD4+ T lymphocytes by major histocompatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy. Cancer Res 64:1867-1874
50. Haque MA, Hawes JW, Blum JS (2001) Cysteinylation of an MHC class II ligand: importance endocytosis and reductive processing in T cell recognition. J Immunol 166:4543-4551